21 April 2026
Eli Lilly's $7B Kelonia Buy Boosts CAR-T Tech | Pharma and Biotech Daily
Pharma and BioTech Daily
About
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic moves that are reshaping the landscape of drug development and patient care.
In vaccine development, Sanofi has recently reported promising results from a comparative trial of its protein-based COVID-19 vaccine, Nuvaxovid, against Moderna’s latest mRNA vaccine, MNEXspike. The focus here was primarily on tolerability, and Sanofi's candidate demonstrated a superior safety profile. This marks a significant moment in the ongoing evolution of vaccine technology, underscoring the importance of diversifying vaccine platforms to effectively address global public health challenges.
Shifting to regulatory landscapes, the U.S. Food and Drug Administration has been tasked with expediting the review process for psychedelic drugs under a directive from former President Donald Trump. This move aims to enhance access to novel treatments for serious mental health conditions, reflecting a broader trend in medicine towards exploring therapeutic avenues beyond traditional pharmaceuticals. It highlights an increasing openness to alternative therapies that could potentially transform mental health care.
Strategic acquisitions continue to fuel innovation within the sector. Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion is particularly noteworthy. This investment marks Lilly's second venture into in vivo CAR-T technology this year, emphasizing its commitment to advancing cell-based therapies. Kelonia's work on phase 1-stage myeloma therapy showcases the potential of CAR-T modalities in treating complex diseases, promising expanded treatment options for patients.
Globally, infrastructure development is gaining momentum with Biovac securing a $108 million finance package to establish Africa's first fully integrated vaccine production facility. This initiative is crucial for enhancing regional healthcare autonomy by addressing local health needs and reducing reliance on external supply chains—a step forward in building resilient healthcare systems.
In oncology, Merck & Co. has unveiled clinical data for its PD-1xVEGF bispecific antibody in non-small cell lung cancer (NSCLC). The results reveal similar efficacy and safety profiles compared to existing treatments, suggesting promising prospects for this bispecific approach in oncology therapeutics. Bispecific antibodies are engineered to engage two different targets simultaneously, potentially enhancing anti-tumor efficacy by not only stimulating immune responses but also disrupting angiogenesis. This innovation represents a continued focus on targeted cancer therapies that enhance treatment precision.
Similarly, AstraZeneca's IL-33 inhibitor has achieved another phase 3 success in treating chronic obstructive pulmonary disease (COPD). This reinforces the therapeutic potential of targeting interleukin pathways in inflammatory diseases and reflects AstraZeneca's strategic focus on respiratory conditions. Such successes highlight the promise of precision medicine in improving patient outcomes.
On the topic of market expansion, GlaxoSmithKline’s multiple myeloma treatment Blenrep has entered the Chinese market. This move exemplifies the growing importance of global market access strategies, ensuring that patients worldwide can benefit from cutting-edge therapies.
Now let’s turn our attention to some intriguing scientific developments. A former Genentech leader has launched a synthetic design lab focused on adaptive "smart" antibody-drug conjugates (ADCs) for cancer therapy. ADCs represent a significant leap forward in precision medicine by offering targeted cancer treatments that minimize damage to healthy cells. These "smart" ADCs could provide more effective and less toxic options for cancer patients.
In vaccine development, Sanofi has recently reported promising results from a comparative trial of its protein-based COVID-19 vaccine, Nuvaxovid, against Moderna’s latest mRNA vaccine, MNEXspike. The focus here was primarily on tolerability, and Sanofi's candidate demonstrated a superior safety profile. This marks a significant moment in the ongoing evolution of vaccine technology, underscoring the importance of diversifying vaccine platforms to effectively address global public health challenges.
Shifting to regulatory landscapes, the U.S. Food and Drug Administration has been tasked with expediting the review process for psychedelic drugs under a directive from former President Donald Trump. This move aims to enhance access to novel treatments for serious mental health conditions, reflecting a broader trend in medicine towards exploring therapeutic avenues beyond traditional pharmaceuticals. It highlights an increasing openness to alternative therapies that could potentially transform mental health care.
Strategic acquisitions continue to fuel innovation within the sector. Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion is particularly noteworthy. This investment marks Lilly's second venture into in vivo CAR-T technology this year, emphasizing its commitment to advancing cell-based therapies. Kelonia's work on phase 1-stage myeloma therapy showcases the potential of CAR-T modalities in treating complex diseases, promising expanded treatment options for patients.
Globally, infrastructure development is gaining momentum with Biovac securing a $108 million finance package to establish Africa's first fully integrated vaccine production facility. This initiative is crucial for enhancing regional healthcare autonomy by addressing local health needs and reducing reliance on external supply chains—a step forward in building resilient healthcare systems.
In oncology, Merck & Co. has unveiled clinical data for its PD-1xVEGF bispecific antibody in non-small cell lung cancer (NSCLC). The results reveal similar efficacy and safety profiles compared to existing treatments, suggesting promising prospects for this bispecific approach in oncology therapeutics. Bispecific antibodies are engineered to engage two different targets simultaneously, potentially enhancing anti-tumor efficacy by not only stimulating immune responses but also disrupting angiogenesis. This innovation represents a continued focus on targeted cancer therapies that enhance treatment precision.
Similarly, AstraZeneca's IL-33 inhibitor has achieved another phase 3 success in treating chronic obstructive pulmonary disease (COPD). This reinforces the therapeutic potential of targeting interleukin pathways in inflammatory diseases and reflects AstraZeneca's strategic focus on respiratory conditions. Such successes highlight the promise of precision medicine in improving patient outcomes.
On the topic of market expansion, GlaxoSmithKline’s multiple myeloma treatment Blenrep has entered the Chinese market. This move exemplifies the growing importance of global market access strategies, ensuring that patients worldwide can benefit from cutting-edge therapies.
Now let’s turn our attention to some intriguing scientific developments. A former Genentech leader has launched a synthetic design lab focused on adaptive "smart" antibody-drug conjugates (ADCs) for cancer therapy. ADCs represent a significant leap forward in precision medicine by offering targeted cancer treatments that minimize damage to healthy cells. These "smart" ADCs could provide more effective and less toxic options for cancer patients.
Support the show